Latest news

• Gilead says switching studies back new HIV therapy Biktarvy

  The results of Study 1844 showed that patients who transferred to treatment with Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) from Triumeq (abacavir/dolutegravir/lamivudine) were able to maintain their viral suppression over

• Gilead’s triple HIV drug approval prompts GSK lawsuit

  Gilead’ s triple HIV drug approval prompts GSK lawsuit. ViiV claims bictegravir infringes its patent estate. ... GSK’s ViiV Healthcare unit has filed a lawsuit against Gilead claiming that its integrase inhibitor bictegravir - which is one of the

• GSK’s ViiV gets US okay for two-drug HIV regimen

  that adds integrase inhibitor bictegravir to the two ingredients in its fast-growing Descovy (emtricitabine/tenofovir alafenamide) product.

• ViiV files two-drug HIV maintenance regimen

  Gilead has just reported the results of four phase III trials of its three-drug combo of new integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide, showing non-inferiority to

• Gilead plans fightback against HIV arch-rival ViiV

  Gilead has reported the results of four phase III trials of a new HIV combination therapy pairing its Descovy product with new candidate bictegravir, and says it is ready to press ... The fixed dose combination of integrase strand inhibitor bictegravir